Ocumension Therapeutics (1477.HK)
HKD 4.56
(-1.72%)
HKD 4.56
(-1.72%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 5.65 Million CNY | -67.29% |
| 2022 | 17.29 Million CNY | 146.11% |
| 2021 | 7.02 Million CNY | 32.34% |
| 2020 | 5.3 Million CNY | -99.84% |
| 2019 | 3.31 Billion CNY | 633249.24% |
| 2018 | 524 Thousand CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q1 | 11.33 Million CNY | -34.48% |
| 2023 Q4 | 5.65 Million CNY | 0.0% |
| 2023 Q2 | 11.33 Million CNY | 0.0% |
| 2023 Q3 | 5.65 Million CNY | -50.07% |
| 2023 FY | 5.65 Million CNY | -67.29% |
| 2022 Q1 | 25.16 Million CNY | 258.23% |
| 2022 Q4 | 17.29 Million CNY | 0.0% |
| 2022 Q3 | 17.29 Million CNY | -31.3% |
| 2022 Q2 | 25.16 Million CNY | 0.0% |
| 2022 FY | 17.29 Million CNY | 146.11% |
| 2021 Q1 | 8.43 Million CNY | 58.79% |
| 2021 FY | 7.02 Million CNY | 32.34% |
| 2021 Q3 | 7.02 Million CNY | -16.65% |
| 2021 Q2 | 8.43 Million CNY | 0.0% |
| 2021 Q4 | 7.02 Million CNY | 0.0% |
| 2020 Q3 | 5.3 Million CNY | -99.89% |
| 2020 Q4 | 5.3 Million CNY | 0.0% |
| 2020 FY | 5.3 Million CNY | -99.84% |
| 2020 Q1 | 4.83 Billion CNY | 45.55% |
| 2020 Q2 | 4.83 Billion CNY | 0.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 Q4 | 3.31 Billion CNY | 0.0% |
| 2019 Q3 | 3.31 Billion CNY | 0.0% |
| 2019 FY | 3.31 Billion CNY | 633249.24% |
| 2018 FY | 524 Thousand CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 30.61 Million HKD | 81.52% |
| CK Life Sciences Int'l., (Holdings) Inc. | 4.27 Billion HKD | 99.868% |